House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Irritable bowel syndrome in adults: diagnosis and management

NICE · 2017 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (CG61) covers how to diagnose and manage irritable bowel syndrome (IBS) in adults. Its recommendations date from 2008, 2015 and 2017. It describes when to consider assessment, which red flags need secondary-care referral, the positive diagnostic criteria, and a limited set of tests to exclude other diagnoses. Management covers self-help, physical activity and dietary advice, specialist dietary management such as low FODMAP, and symptom-directed drugs. The drug options include antispasmodics, laxatives, linaclotide, loperamide and low-dose antidepressants. It also covers psychological referral for refractory IBS, discouraged complementary therapies, and agreed follow-up.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Clinical assessment and diagnosis

  • Consider assessment for IBS when a person reports any of the following for at least 6 months: abdominal pain or discomfort, bloating, or a change in bowel habit. [1]
  • Assess and clinically examine everyone with possible IBS symptoms for red flags. Refer to secondary care for further investigation if there are signs or symptoms of cancer (as defined in NICE suspected cancer guidance) or inflammatory markers for inflammatory bowel disease. [1]
  • Consider an IBS diagnosis only if abdominal pain or discomfort is relieved by defaecation or linked to altered bowel frequency or stool form. At least 2 of 4 further symptoms must also be present: altered stool passage (straining, urgency, incomplete evacuation); bloating, distension, tension or hardness; symptoms worsened by eating; or mucus. Lethargy, nausea, backache and bladder symptoms may support the diagnosis. [1]
  • Characterise the quantity, quality and site of the pain, and whether the site varies. A varying site helps distinguish IBS from cancer-related pain, which is typically fixed. [1]
  • The Bristol Stool Form Scale may help people describe their bowel habit. Ask open questions about how symptoms affect daily life, because about 20% of people with faecal incontinence disclose it only if asked. [1]

Diagnostic tests

  • In people meeting the diagnostic criteria, check FBC, ESR or plasma viscosity, CRP, and coeliac antibodies (EMA or TTG) to exclude other diagnoses. [1]
  • Ultrasound, sigmoidoscopy (rigid or flexible), colonoscopy, barium enema, thyroid function, faecal ova and parasites, faecal occult blood, and hydrogen breath testing are not needed to confirm IBS in people who meet the criteria. [1]

Self-help and lifestyle

  • Provide information on the importance of self-help, covering lifestyle, physical activity, diet and symptom-targeted medication. Encourage people to make use of leisure time and to create time for relaxation. [1]
  • Assess physical activity, ideally with the GPPAQ. Give people with low activity brief advice and counselling to increase it. [1]

Dietary management

  • Assess diet and give general advice: - Eat regular, unhurried meals without long gaps. - Drink at least 8 cups of fluid daily, preferably non-caffeinated. - Limit tea and coffee to 3 cups daily. - Cut down on alcohol and fizzy drinks. [1]
  • Limiting high-fibre foods may help. Reduce resistant starch, which is common in processed or re-cooked foods. Limit fresh fruit to 3 portions daily, with a portion of approximately 80 g. [1]
  • People with diarrhoea should avoid sorbitol. Those with wind and bloating may benefit from oats and linseeds (up to 1 tablespoon daily). [1]
  • Review fibre intake and adjust it, usually downward, while monitoring symptoms. Discourage insoluble fibre such as bran. If more fibre is advised, use soluble fibre such as ispaghula or oats. [1]
  • People who choose to try probiotics should take them at the manufacturer's dose for at least 4 weeks, monitoring the effect. [1]
  • If symptoms persist despite general advice, offer further dietary management, including single food avoidance and exclusion diets such as low FODMAP. This advice should be given only by a professional with expertise in dietary management. [1]

Pharmacological therapy

  • Base drug choice on the nature and severity of the predominant symptoms. Consider antispasmodics, taken as required alongside dietary and lifestyle advice. [1]
  • Consider laxatives for constipation, but discourage lactulose. [1]
  • Consider linaclotide only when optimal or maximum tolerated doses of laxatives from different classes have failed and constipation has lasted at least 12 months. Review after 3 months. [1]
  • Loperamide is the first-choice antimotility agent for diarrhoea. Advise people to titrate laxative or antimotility doses to stool consistency, aiming for Bristol type 4. [1]
  • Consider TCAs second-line if laxatives, loperamide or antispasmodics have not helped. Start at 5 mg to 10 mg amitriptyline-equivalent once at night and review regularly. Do not usually exceed 30 mg. TCAs were unlicensed for this indication as of February 2015. [1]
  • Consider SSRIs only if TCAs are ineffective. Weigh side effects for both drug classes. When either is started at low dose for pain or discomfort, follow up after 4 weeks and then every 6 to 12 months. [1]

Psychological therapy, complementary medicine and follow-up

  • Consider referral for CBT, hypnotherapy or psychological therapy in refractory IBS, defined as no response to drug treatment after 12 months with a continuing symptom profile. [1]
  • Discourage aloe vera, and do not encourage acupuncture or reflexology, for IBS. [1]
  • Agree follow-up with the person based on symptom response, as part of the annual review. New red-flag symptoms should prompt further investigation or referral to secondary care. [1]

Limitations and use

  • The guideline applies to adults only; children and young people are not covered.
  • Recommendation 1.1.1.3 has been withdrawn and is not summarised.
  • Cross-referenced NICE guidance on suspected cancer referral and on medicines associated with dependence or withdrawal is not reproduced here. The criteria for cancer red flags must be taken from that guidance.
  • Appendices of the full guideline (Bristol Stool Form Scale, GPPAQ) and any tables or flowcharts were not reviewed.
  • Research recommendations and rationale or update sections were excluded.
  • The off-label status of TCAs and SSRIs is stated as at February 2015; current licensing should be checked locally.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Irritable bowel syndrome in adults: diagnosis and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
23 February 2008
Publisher’s latest update
4 April 2017
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Clinical assessment and diagnosis
  • Diagnostic tests
  • Self-help and lifestyle
  • Dietary management
  • Pharmacological therapy
  • Psychological therapy, complementary medicine and follow-up
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House